SCHEMBL15065727

SCHEMBL15065727

CC(C)(C)OC(=O)N1CCN(c2ccc3cc(-c4nc5ccccc5s4)c(=O)oc3c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.55
PIK3CD O00329 1/20 0.55
PIK3CB P42338 1/20 0.55
GPR119 Q8TDV5 2/20 0.45
ATR Q13535 1/20 0.44
PDK2 Q15119 1/20 0.43
BACE1 P56817 2/20 0.43
GBA1 P04062 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.41
PIK3CA P42336 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
DYRK1A Q13627 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15065811 0.87 PIK3CD (0.43) ALKPIK3CDPIK3CBGPR119ATR
SCHEMBL15066000 0.87 ALK (0.46) ALKPIK3CDPIK3CBPDK2BACE1
SCHEMBL15230503 0.87 PIK3CD (0.48) ALKPIK3CDPIK3CBGPR119ATR
SCHEMBL4505982 0.84 PIK3CD (0.62) ALKPIK3CDPIK3CBIRAK4NPC1
SCHEMBL16674768 0.82 PIK3CD (0.64) ALKPIK3CDPIK3CBNPC1RAB9A
SCHEMBL15069039 0.81 PIK3CD (0.59) ALKPIK3CDPIK3CBNPC1RAB9A
SCHEMBL4505188 0.81 PIK3CD (0.63) ALKPIK3CDPIK3CBIRAK4NPC1
SCHEMBL15264454 0.81 GPR119 (0.44) GPR119ATRPDK2BACE1GBA1
SCHEMBL15068911 0.81 PIK3CD (0.58) ALKPIK3CDPIK3CBIRAK4NPC1
SCHEMBL25997259 0.80 PIK3CD (0.60) ALKPIK3CDPIK3CBIRAK4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
EP-2797592-B1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS INC (US) 2019-08-28 EP disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 ALK 4482/4885PIK3CD 3763/4885PIK3CB 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.